Physician profile
Douglas Bishop
NPI 1437354883
$1,267.40
in general payments reported to CMS, 2019-2025
24 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $158 · 2021: $58.04 · 2022: $292 · 2023: $104 · 2024: $162 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $171.03 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Gilead Sciences, INC. | $135.06 | 2019-2022 | |
| Braeburn INC. | $126.96 | 2023-2025 | Brixadi |
| Medtronic, INC. | $107.97 | 2022-2025 | Minimed 780g |
| Glaxosmithkline, LLC. | $105.68 | 2019-2022 | |
| Alkermes, INC. | $92.68 | 2024-2025 | Vivitrol |
| Indivior INC. | $75.10 | 2020-2025 | Sublocade |
| Pfizer INC. | $64.50 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $64.14 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $55.35 | 2019-2020 | |
| Abbvie INC. | $54.21 | 2019-2022 | |
| Amgen INC. | $28.42 | 2024 | Otezla, Repatha |
| Novo Nordisk INC | $25.49 | 2019-2021 | |
| Lilly USA, LLC | $19.89 | 2025 | Zepbound |
| Hologic Sales and Service, LLC | $17.79 | 2025 | Aptima |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.02 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2022 | |
| Phadia US INC. | $14.56 | 2020 | |
| Sanofi Pasteur INC. | $13.70 | 2022 | |
| Ibsa Pharma INC. | $13.39 | 2023 | Tirosint, Licart |
| Smith+Nephew, INC. | $13.04 | 2019 | |
| Allergan, INC. | $12.92 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.